Autoimmun vermittelte Enzephalitis

Autoimmunenzephalitiden bilden eine heterogene Gruppe neurologischer und psychiatrischer Erkrankungen. Es werden Antikörper-vermittelte Enzephalitiden von den häufig paraneoplastisch auftretenden Antikörper-assoziierten Enzephalitiden unterschieden. Während die Antikörper im ersten Fall direkt krankheitsverursachend sind, dienen sie im zweiten Fall als diagnostischer Biomarker mit hoher Aussagekraft für einen zugrunde liegenden Tumor.

Abstract

Autoimmune encephalitides form a heterogeneous group of neurological and psychiatric diseases. In antibody-mediated encephalitis, autoantibodies are pathogenic and directly cause the encephalitis. In antibody-associated encephalitis, which is paraneoplastic most of the time, autoantibodies serve as diagnostic biomarkers and are able to predict the underlying tumour.

Schlüsselwörter

Autoimmun-Enzephalitis - Antikörper - paraneoplastisch

Key words

autoimmune encephalitis - antibody - paraneoplastic

Publication History

Article published online:
07 November 2022

• Literatur

• 1 Prüss H.. Autoantibodies in neurological disease. Nat Rev Immunol 2021; 21: 798-813
• 2 Graus F, Titulaer MJ, Balu R. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404
• 3 Dalmau J, Armangué T, Planaguma J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019; 18: 1045-1057
• 4 Dalmau J, Graus F.. Antibody-Mediated Encephalitis. N Engl J Med 2018; 378: 840-851
• 5 Prüss H, Finke C, Holtje M. et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911
• 6 Armangué T, Spatola M, Vlagea A. et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772
• 7 Graus F, Vogrig A, Muniz-Castrillo S. et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014
• 8 Graus F, Delattre JY, Antoine JC. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140
• 9 Saiz A, Blanco Y, Sabater L. et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563
• 10 Graus F, Dalmau J.. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Reviews Clin Oncol 2019; 16: 535-548
• 11 Herken J, Prüss H.. Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients. Front Psychiatry 2017; 8: 25
• 12 Rößling R, Prüss H.. Apheresis in Autoimmune Encephalitis and Autoimmune Dementia. J Clin Med 2020; 9: 2683
• 13 Gelpi E, Hoftberger R, Graus F. et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132: 531-543
• 14 Werner J, Jelcic I, Schwarz EI. et al. Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome. Neurol Neuroimmunol Neuroinflamm 2021; 8: e962
• 15 Blinder T, Lewerenz J.. Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis. Front Neurol 2019; 10: 804
• 16 Schmitt SE, Pargeon K, Frechette ES. et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79: 1094-1100
• 17 Gultekin SH, Rosenfeld MR, Voltz R. et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123: 1481-1494
• 18 Scheibe F, Prüss H, Mengel AM. et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88: 366-370
• 19 Wickel J, Chung HY, Platzer S. et al. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials 2020; 21: 625
• 20 van Sonderen A, Thijs RD, Coenders EC. et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456
• 21 Finke C, Prüss H, Heine J. et al. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurol 2017; 74: 50-59